FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058285887> ?p ?o ?g. }

• W2058285887 endingPage "319" @default.
• W2058285887 startingPage "311" @default.
• W2058285887 abstract "Between January 2001 and September 2007, we treated 54 metastatic melanoma patients with patient-specific tumor cell vaccines consisting of dendritic cells (DCS), derived from their peripheral blood cells that were cultured in interleukin (IL)-4 and granulocyte macrophage colony-stimulating factor (GM-CSF), which had phagocytosed irradiated autologous tumor cells from a continuously proliferating, self-renewing, autologus tumor cell (TC) culture. The loaded DCs were injected subcutaneously in 500 μg of GM-CSF weekly x three, and then monthly for 5 months, for a total of up to 8 injections. The 34 men and 20 women had a median age of 50.5 years; 32 had M1c (visceral metastases and/or elevated lactate dehydrogenase) as their most advanced disease stage. Overall, 83% had received other systemic therapies, including interferon-alpha (n = 20), biochemotherapy (n = 19), GM-CSF (n = 19), chemotherapy (n = 16), IL-2 (n = 13), and other investigational vaccines (n = 7). Patients received an average of 7.4 vaccinations. Treatment was well-tolerated, with most patients experiencing only mild local pruritus and/or erythema. A positive delayed-type hypersensitivity reaction to purified autologous tumor cells was observed at baseline in only 1 of 54 patients, compared to 12 of 54 following vaccination (p = 0.001). The projected 5-year survival rate is an impressive 54% at a median follow-up of 4.5 years (range, 2.4–7.4) for the 30 surviving patients. This survival was superior to that observed following vaccination with irradiated TC in 48 melanoma patients in a previous trial (64 versus 31 months, p = 0.016). This patient-specific vaccine warrants further investigation, based on its safety and encouraging survival rates. (Clinical Trial Number: NCI-V01-1646)." @default.
• W2058285887 created "2016-06-24" @default.
• W2058285887 creator A5005033200 @default.
• W2058285887 creator A5009084198 @default.
• W2058285887 creator A5013377891 @default.
• W2058285887 creator A5016651521 @default.
• W2058285887 creator A5049869264 @default.
• W2058285887 creator A5052609567 @default.
• W2058285887 creator A5062081483 @default.
• W2058285887 creator A5063296555 @default.
• W2058285887 creator A5088579860 @default.
• W2058285887 creator A5088803451 @default.
• W2058285887 date "2009-06-01" @default.
• W2058285887 modified "2023-09-26" @default.
• W2058285887 title "Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report" @default.
• W2058285887 cites W1951046932 @default.
• W2058285887 cites W1968375892 @default.
• W2058285887 cites W1975563834 @default.
• W2058285887 cites W1986523328 @default.
• W2058285887 cites W1994421771 @default.
• W2058285887 cites W1997006445 @default.
• W2058285887 cites W1997919830 @default.
• W2058285887 cites W1998547530 @default.
• W2058285887 cites W2015399916 @default.
• W2058285887 cites W2043950983 @default.
• W2058285887 cites W2049339266 @default.
• W2058285887 cites W2053079899 @default.
• W2058285887 cites W2055863561 @default.
• W2058285887 cites W2061234917 @default.
• W2058285887 cites W2088406879 @default.
• W2058285887 cites W2088658776 @default.
• W2058285887 cites W2130760938 @default.
• W2058285887 cites W2137723371 @default.
• W2058285887 cites W2140715248 @default.
• W2058285887 cites W2160684797 @default.
• W2058285887 cites W2164584613 @default.
• W2058285887 cites W2165930560 @default.
• W2058285887 cites W2180474870 @default.
• W2058285887 cites W2074063867 @default.
• W2058285887 doi "https://doi.org/10.1089/cbr.2008.0599" @default.
• W2058285887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19538053" @default.
• W2058285887 hasPublicationYear "2009" @default.
• W2058285887 type Work @default.
• W2058285887 sameAs 2058285887 @default.
• W2058285887 citedByCount "61" @default.
• W2058285887 countsByYear W20582858872012 @default.
• W2058285887 countsByYear W20582858872013 @default.
• W2058285887 countsByYear W20582858872014 @default.
• W2058285887 countsByYear W20582858872015 @default.
• W2058285887 countsByYear W20582858872016 @default.
• W2058285887 countsByYear W20582858872017 @default.
• W2058285887 countsByYear W20582858872018 @default.
• W2058285887 countsByYear W20582858872019 @default.
• W2058285887 countsByYear W20582858872020 @default.
• W2058285887 countsByYear W20582858872021 @default.
• W2058285887 countsByYear W20582858872022 @default.
• W2058285887 countsByYear W20582858872023 @default.
• W2058285887 crossrefType "journal-article" @default.
• W2058285887 hasAuthorship W2058285887A5005033200 @default.
• W2058285887 hasAuthorship W2058285887A5009084198 @default.
• W2058285887 hasAuthorship W2058285887A5013377891 @default.
• W2058285887 hasAuthorship W2058285887A5016651521 @default.
• W2058285887 hasAuthorship W2058285887A5049869264 @default.
• W2058285887 hasAuthorship W2058285887A5052609567 @default.
• W2058285887 hasAuthorship W2058285887A5062081483 @default.
• W2058285887 hasAuthorship W2058285887A5063296555 @default.
• W2058285887 hasAuthorship W2058285887A5088579860 @default.
• W2058285887 hasAuthorship W2058285887A5088803451 @default.
• W2058285887 hasConcept C126322002 @default.
• W2058285887 hasConcept C203014093 @default.
• W2058285887 hasConcept C2776178377 @default.
• W2058285887 hasConcept C2776694085 @default.
• W2058285887 hasConcept C2777478134 @default.
• W2058285887 hasConcept C2777658100 @default.
• W2058285887 hasConcept C2777701055 @default.
• W2058285887 hasConcept C2778690821 @default.
• W2058285887 hasConcept C2781228144 @default.
• W2058285887 hasConcept C2909179924 @default.
• W2058285887 hasConcept C502942594 @default.
• W2058285887 hasConcept C71924100 @default.
• W2058285887 hasConcept C8891405 @default.
• W2058285887 hasConcept C90924648 @default.
• W2058285887 hasConceptScore W2058285887C126322002 @default.
• W2058285887 hasConceptScore W2058285887C203014093 @default.
• W2058285887 hasConceptScore W2058285887C2776178377 @default.
• W2058285887 hasConceptScore W2058285887C2776694085 @default.
• W2058285887 hasConceptScore W2058285887C2777478134 @default.
• W2058285887 hasConceptScore W2058285887C2777658100 @default.
• W2058285887 hasConceptScore W2058285887C2777701055 @default.
• W2058285887 hasConceptScore W2058285887C2778690821 @default.
• W2058285887 hasConceptScore W2058285887C2781228144 @default.
• W2058285887 hasConceptScore W2058285887C2909179924 @default.
• W2058285887 hasConceptScore W2058285887C502942594 @default.
• W2058285887 hasConceptScore W2058285887C71924100 @default.
• W2058285887 hasConceptScore W2058285887C8891405 @default.
• W2058285887 hasConceptScore W2058285887C90924648 @default.
• W2058285887 hasIssue "3" @default.
• W2058285887 hasLocation W20582858871 @default.

• next